BD Plays It Safe
Executive Summary
It's not often that a company gets the chance to, in effect, reinvent a major product category. Moreover, it's not often that government legislators and regulators give the company a significant boost in its effort. But that's exactly what's happened for sharps product leader Becton Dickinson & Co. As concerns about health care worker safety mount, legislation recently enacted in California requires hospitals to convert from severly price-squeezed conventional sharps products to new, specially-designed products--a kind of decommoditization of these highly commoditized product categories. And BD officials hope the California law is only the beginning.
You may also be interested in...
TORL Looks To Break Ground In Growing Field Of Claudin-Targeting Drugs
The company announced a series B-2 financing of $158m that it plans to use for pivotal Phase II development of TORL-1-23, which it called a first-in-class agent.
‘Biggest Transformation In The History Of Medicine’: Oncologist And Cardiologist Talk AI-Enabled Health Care
At the recent Precision Med Tri-Con conference, health care leaders and AI enthusiasts Eric Topol and Doug Flora discussed how AI integration will change the way doctors practice medicine and patients receive care.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.